Cost-effectiveness of trastuzumab biosimilar combination therapy and drug wastage as first-line treatment for HER2-positive metastatic breast cancer - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35870421/
doi: 10.1016/j.breast.2022.07.007. Online ahead of print. 1 Department of Obstetrics and Gynecology, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chiayi, Taiwan. Electronic address: [email protected]. 2 Department of Surgery, An-Nan Hospital, China Medical University, Tainan, Taiwan. Electronic address: [email protected]. 3 Department of Radiology, An-Nan Hospital, China Medical University, Tainan, Taiwan. Electronic address: [email protected].
Conclusion: The trastuzumab biosimilar combination regimen is cost-effective and offers significant drug cost savings in Taiwan.